POP QUIZ: Rinvoq for inflammatory bowel diseaseAll of the following statements about the use of Rinvoq (upadacitinib) in inflammatory bowel disease are true, EXCEPT for . . . Rinvoq (upadacitinib) now indicated for moderate/severely active Crohn’s diseaseIt is the first oral Janus kinase (JAK) inhibitor indicated for acute treatment and maintenance therapy in both Crohn's disease and ulcerative colitis in adults. Could probiotics play a real role in ameliorating major depressive disorder? Pilot study looks at acceptability, tolerability and estimated effect sizes on key clinical outcomes. The link between stress hormones and better digestive health Researcher says understanding how cortisol acts will open doors to new treatments for those struggling with digestive issues. Curcumin and omeprazole have similar efficacy in dyspepsia But there’s no added benefit to combining them. Rinvoq approved for use in moderately to severely active ulcerative colitis in adults A new 45 mg extended-release tablet is expected to be available in mid-September for induction dosing in ulcerative colitis. Is it GERD or typical spit up? PPI use in young children may increase risk of serious infections Proton pump inhibitors (PPIs) should not be used without a clear indication in the pediatric population. New U.S. guidelines on the pharmacologic management of chronic idiopathic constipation Provide a comprehensive outline of the various OTC and prescription agents available for the treatment of chronic idiopathic constipation in adults. Sponsored Do you know the management pathway for pancreatic exocrine insufficiency (PEI)? Canadian gastroenterologists weigh in on new celiac disease guidelines Update from the American College of Gastroenterology aimed at supporting clinical practice. First Previous 2 3 4 5 6 Next Last
